Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

61.15
+1.332.22%
Post-market: 61.900.7500+1.23%17:01 EDT
Volume:1.26M
Turnover:76.12M
Market Cap:4.48B
PE:-36.50
High:61.99
Open:59.77
Low:59.47
Close:59.82
52wk High:62.32
52wk Low:14.79
Shares:73.27M
Float Shares:61.73M
Volume Ratio:1.73
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6753
EPS(LYR):-1.8300
ROE:-15.31%
ROA:-11.00%
PB:5.01
PE(LYR):-33.42

Loading ...

Orbimed Advisors Reports Enliven Therapeutics Common Stock Sale Worth $38.02 Million

Reuters
·
Jun 25

Enliven Therapeutics CMO Helen Louise Collins disposes of USD 217,816 in common shares

Reuters
·
Jun 23

OrbiMed Advisors reports $12.67 million Enliven Therapeutics common stock sale

Reuters
·
Jun 18

Enliven Therapeutics Closes Upsized $460 Million Public Offering

MT Newswires Live
·
Jun 16

Enliven Therapeutics closes upsized public offering, raises USD 460 million gross

Reuters
·
Jun 16

Jefferies Remains a Buy on Enliven Therapeutics (ELVN)

TIPRANKS
·
Jun 15

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Twist Bioscience (TWST)

TIPRANKS
·
Jun 15

Why Is Enliven Therapeutics Stock (ELVN) Up Today?

TIPRANKS
·
Jun 13

Enliven rises 9.9%

TIPRANKS
·
Jun 13

BUZZ-Enliven soars after boosted equity raise for leukemia drug

Reuters
·
Jun 12

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of SpaceX Debut

MT Newswires Live
·
Jun 12

Enliven Therapeutics Prices $400 Million Public Offering

MT Newswires Live
·
Jun 12

BRIEF-Enliven Therapeutics Prices 8.9 Million Shares At $37.50 Per Share

Reuters
·
Jun 12

Enliven Therapeutics prices upsized public offering at $37.5 per share, targets $400 million gross proceeds

Reuters
·
Jun 12

Enliven: Prices 8.9 Mln Shares at $37.50 per Share

THOMSON REUTERS
·
Jun 12

BRIEF-Enliven Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants

Reuters
·
Jun 12

Enliven Therapeutics launches USD 250 million stock, pre-funded warrant offering

Reuters
·
Jun 12

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Jun 12

Boris Peaker Reiterates Buy Rating and $45 Price Target on ELVN-001 After Strong Phase 1b CML Data Support Best-in-Class Potential

TIPRANKS
·
Jun 11

Enliven rises 14.8%

TIPRANKS
·
Jun 11